A citation-based method for searching scientific literature

Veronica Valvo, Carmelo Nucera. Endocrinol Metab Clin North Am 2019
Times Cited: 8







List of co-cited articles
25 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
50


BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.
Gerald S Falchook, Michael Millward, David Hong, Aung Naing, Sarina Piha-Paul, Steven G Waguespack, Maria E Cabanillas, Steven I Sherman, Bo Ma, Martin Curtis,[...]. Thyroid 2015
105
25

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
25

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
164
25

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
146
25

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
839
25

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
300
25

Squamous cells in the human thyroid gland.
V A LiVolsi, M J Merino. Am J Surg Pathol 1978
77
25


Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
463
25

The variable presentations of anaplastic spindle cell squamous carcinoma associated with tall cell variant of papillary thyroid carcinoma.
Pallavi P Gopal, Kathleen T Montone, Zubair Baloch, Madalina Tuluc, Virginia LiVolsi. Thyroid 2011
27
25

Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
Naoki Oishi, Tetsuo Kondo, Aya Ebina, Yukiko Sato, Junko Akaishi, Rumi Hino, Noriko Yamamoto, Kunio Mochizuki, Tadao Nakazawa, Hiroshi Yokomichi,[...]. Mod Pathol 2017
40
25

Squamous cell carcinoma of the thyroid gland: primary or secondary disease?
M I Syed, M Stewart, S Syed, S Dahill, C Adams, D R McLellan, L J Clark. J Laryngol Otol 2011
47
25

Thyroid carcinoma with papillary and squamous features: report of a case with histogenetic considerations.
Th Rausch, J Benhattar, M Sutter, S Andrejevic-Blant. Pathol Res Pract 2010
17
25




Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Seung Eun Lee, Tae Sook Hwang, Yoon-La Choi, Hye Seung Han, Wan Seop Kim, Min Hye Jang, Suk Kyeong Kim, Jung Hyun Yang. Thyroid 2016
42
25

clusterProfiler: an R package for comparing biological themes among gene clusters.
Guangchuang Yu, Li-Gen Wang, Yanyan Han, Qing-Yu He. OMICS 2012
25

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
390
25

ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Catarina Tavares, Miguel Melo, José Manuel Cameselle-Teijeiro, Paula Soares, Manuel Sobrinho-Simões. Eur J Endocrinol 2016
45
25

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,[...]. Proc Natl Acad Sci U S A 2005
25

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
549
25

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
696
25



E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion.
Hilary Glen, Susan Mason, Hitesh Patel, Kenneth Macleod, Valerie G Brunton. BMC Cancer 2011
56
12

Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.
Abdul K Siraj, Tariq Masoodi, Rong Bu, Shaham Beg, Saif S Al-Sobhi, Fouad Al-Dayel, Mohammed Al-Dawish, Fowzan S Alkuraya, Khawla S Al-Kuraya. Am J Hum Genet 2016
32
12

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, Vatche Tchekmedyian, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra,[...]. J Clin Endocrinol Metab 2019
57
12

Inferring tumor progression from genomic heterogeneity.
Nicholas Navin, Alexander Krasnitz, Linda Rodgers, Kerry Cook, Jennifer Meth, Jude Kendall, Michael Riggs, Yvonne Eberling, Jennifer Troge, Vladimir Grubor,[...]. Genome Res 2010
330
12

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.
Nikhil Wagle, Caroline Emery, Michael F Berger, Matthew J Davis, Allison Sawyer, Panisa Pochanard, Sarah M Kehoe, Cory M Johannessen, Laura E Macconaill, William C Hahn,[...]. J Clin Oncol 2011
691
12

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikos I Poulikakos, Chao Zhang, Gideon Bollag, Kevan M Shokat, Neal Rosen. Nature 2010
12

Evolution of the cancer genome.
Lucy R Yates, Peter J Campbell. Nat Rev Genet 2012
370
12

Methods of measurement for tumor mutational burden in tumor tissue.
Bárbara Meléndez, Claude Van Campenhout, Sandrine Rorive, Myriam Remmelink, Isabelle Salmon, Nicky D'Haene. Transl Lung Cancer Res 2018
87
12

Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Alessandro Prete, Agnes S Lo, Peter M Sadow, Swati S Bhasin, Zeus A Antonello, Danica M Vodopivec, Soumya Ullas, Jennifer N Sims, John Clohessy, Ann M Dvorak,[...]. Clin Cancer Res 2018
23
12

Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.
George N Naumov, Lars A Akslen, Judah Folkman. Cell Cycle 2006
312
12


An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
Yaohua Xue, Luciano Martelotto, Timour Baslan, Alberto Vides, Martha Solomon, Trang Thi Mai, Neelam Chaudhary, Greg J Riely, Bob T Li, Kerry Scott,[...]. Nat Med 2017
81
12

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
327
12


High-definition reconstruction of clonal composition in cancer.
Andrej Fischer, Ignacio Vázquez-García, Christopher J R Illingworth, Ville Mustonen. Cell Rep 2014
100
12

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.
Zeus A Antonello, Nancy Hsu, Manoj Bhasin, Giovanni Roti, Mukta Joshi, Paul Van Hummelen, Emily Ye, Agnes S Lo, S Ananth Karumanchi, Christine R Bryke,[...]. Oncotarget 2017
26
12

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
Junji Matsui, Yuji Yamamoto, Yasuhiro Funahashi, Akihiko Tsuruoka, Tatsuo Watanabe, Toshiaki Wakabayashi, Toshimitsu Uenaka, Makoto Asada. Int J Cancer 2008
313
12

An evolutionary-game model of tumour-cell interactions: possible relevance to gene therapy.
L A Bach, S M Bentzen, J Alsner, F B Christiansen. Eur J Cancer 2001
35
12

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
Matija Snuderl, Ladan Fazlollahi, Long P Le, Mai Nitta, Boryana H Zhelyazkova, Christian J Davidson, Sara Akhavanfard, Daniel P Cahill, Kenneth D Aldape, Rebecca A Betensky,[...]. Cancer Cell 2011
448
12

Tumor heterogeneity: causes and consequences.
Andriy Marusyk, Kornelia Polyak. Biochim Biophys Acta 2010
868
12

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Kerstin Trunzer, Anna C Pavlick, Lynn Schuchter, Rene Gonzalez, Grant A McArthur, Thomas E Hutson, Stergios J Moschos, Keith T Flaherty, Kevin B Kim, Jeffrey S Weber,[...]. J Clin Oncol 2013
270
12

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Brian P Danysh, Erin Y Rieger, Deepankar K Sinha, Caitlin V Evers, Gilbert J Cote, Maria E Cabanillas, Marie-Claude Hofmann. Oncotarget 2016
31
12

Identification of blood vascular endothelial stem cells by the expression of protein C receptor.
Qing Cissy Yu, Wenqian Song, Daisong Wang, Yi Arial Zeng. Cell Res 2016
68
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.